Population-pharmacokinetic/pharmacodynamic model of atractylodes lancea (Thunb.) DC. administration in patients with advanced-stage intrahepatic cholangiocarcinoma: a dosage prediction

Population-pharmacokinetic/pharmacodynamic model of atractylodes lancea (Thunb.) DC. administration in patients with advanced-stage intrahepatic cholangiocarcinoma: a dosage prediction

Abstract Background A recent phase 2A clinical study of Atractylodes lancea (Thunb.) DC. (AL) in patients with advanced-stage intrahepatic cholangiocarcinoma (iCCA) demonstrated significant reduction of the risk of tumor progression and mortality with a dose ranging from 1,000 to 2,000 mg. The prese...

Full description

Bibliographic Details
Main Authors: Teerachat Saeheng, Juntra Karbwang, Kesara Na-Bangchang
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Complementary Medicine and Therapies
Subjects:
Population-pharmacokinetic model
Atractylodes Lancea
Intrahepatic cholangiocarcinoma
Biliary tract cancer
Dose prediction
Clinical study
Online Access:https://doi.org/10.1186/s12906-024-04618-8

Internet

https://doi.org/10.1186/s12906-024-04618-8

Similar Items